GSK

ACCE-researched
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Healthcare · Drug Manufacturers - General · NYSE · United States
$51.08+1.71%
Market cap $100.6BNext earnings 2026-11-04Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$51.08+0.0%
confidence-weighted across 4 of 6 models
Now $51.08
$51.08
$30.13$67.81
TrimBronze43
Price vs fair value
12.7% above
-11.3% to fair value
ACCE score
63
out of 100
Analysts
13% buy
8 covering
P/E
15.9x
forward 9.7x
1-year return
+25.6%
Dividend yield
3.62%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • moderate
    Revenue growth deceleration
    QoQ revenue growth collapsed to -11.5% despite 5y CAGR of 8.1%, signaling potential near-term demand or pipeline headwinds.
  • moderate
    Elevated leverage ratio
    Debt/Equity of 1.03 is meaningful for a pharma major; limits financial flexibility if pipeline setbacks or litigation costs arise.
Reports in 42 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+24.9% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bearish13% buy · 8 covering analysts
● Strong buy 1● Buy 0● Hold 5● Sell 1● Strong sell 1
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x15.9xhigh 36.4x
ROEbetter than 83% of peers
low -21%33%high 47%
Div yieldbetter than 33% of peers
low 2.1%3.6%high 9.6%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
GSK.LGSK$100.7B15.933.4%1.033.6%-Compare
SNYSanofi ADS$101.8B23.05.7%0.269.6%-Compare
SAN.PASanofi$101.9B22.95.7%0.265.5%-Compare
BMYBristol-Myers Squibb Company Common Stock$127.9B13.846.6%2.444.0%-Compare
PFEPfizer Inc. Common Stock$157.7B36.45.0%0.746.2%-Compare
GILDGilead Sciences Inc. Common Stock$186.1B--20.7%1.102.1%-Compare

Sector report card

Where GSK ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 42 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+2.1%
1 month
-2.5%
3 months
-1.9%
6 months
-6.6%
YTD
+4.2%
1 year
+25.6%

SEC filings

40 filings
September 2026
Sep 15
6-KForeign current reportPeriod 2026-09-15
Sep 15
6-KForeign current reportPeriod 2026-09-15
Sep 14
6-KForeign current reportPeriod 2026-09-14
37 more filings + AI summaries on Investor+.INVESTOR